1. Humanized mouse models for preclinical evaluation of novel immune therapies, checkpoint inhibitors and immune cell engagers. (October 2022) Authors: Stecklum, M.; Brzezicha, B.; Rhein, S.; Walther, W.; Hoffmann, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. New patient derived lymphoma xenograft (PDX) panel for drug development, immuno-oncology and translational research. (October 2022) Authors: Brzezicha, B.; Becker, M.; Stecklum, M.; Conrad, T.; Janz, M.; Bittner, A.; Schmitt, C.A.; Hoffmann, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Patient-derived xenografts (PDX) from agressive haematological malignancies. (December 2016) Authors: Brzezicha, B.; Siegert, A.; Walther, W.; Fichtner, I.; Hoffmann, J.; Karawajew, L.; Schmitt, C.; Janz, M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Preclinical models of patient derived xenografts (PDX) for immuno-oncology research. (December 2016) Authors: Stecklum, M.; Wulf-Goldenberg, A.; Brzezicha, B.; Fichtner, I.; Hoffmann, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗